U.S., May 23 -- ClinicalTrials.gov registry received information related to the study (NCT07603050) titled 'A Phase I/II Clinical Study to Evaluate the Safety and Efficacy of VGN-R08b in Patients With Type III Gaucher's Disease' on April 30.
Brief Summary: A phase I/II clinical study to evaluate the tolerance, safety and efficacy of VGN-R08b intracerebroventricular injection in patients with type III Gaucher's disease
Study Start Date: May 14
Study Type: INTERVENTIONAL
Condition:
Gaucher Disease Type 3
Intervention:
DRUG: VGN-R08b
6x10^10 vg/g
DRUG: VGN-R08b
1.2x10^11 vg/g
DRUG: VGN-R08b
1.8x10^11 vg/g
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Shanghai Vitalgen BioPharma Co., Ltd.
Published by HT Digital Content Service...